雄激素非依赖性前列腺癌的研究进展

ial end point for hormone refractory prostatic cancer.J Urol，1992，147（3Pt2）:931-934. 38 Attivissimo LA，Fetten JV，Kreis W.Symptomatic improvement assoc iated with combined estramustine and vinblastine chemotherapy for metas tatic prostate cancer.Am J Clin Oncol，1996，19（6）:581-583. 39 Park DS，Vassilopoulou-Sellin R，Tu S.Estramustine-related hypoc alˉcemia in patients with prostate carcinoma and osteoblastic metastas es.Urology，2001，58（1）:105. 40 Myers C，Cooper M，Stein C，et al.Suramin:A novel growth factor antagˉonist with activity in hormone-refractory metastatic prostate ca ncer.J Clin Oncol，1992，10:881. 41 Eisenberger MA，Sinibaldi VJ，Reyno LM，et al.Phase I and clinic al eˉvaluation of a pharmacologically guided regimen of suramin in pat ients with hormone-refractory prostate cancer.J Clin Oncol，1995，13（9 ）:2174-2186. 42 Bonham MJ，Galkin A，Montgomery B，et al.Effects of the herbal e xtract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition.J Natl Cancer Inst，2002，94（21）:1641-1647. 　　作者单位:100020首都医科大学附属北京朝阳医院泌尿外科 中华现代外科学杂志 2004年10月 第1卷 第3期

《雄激素非依赖性前列腺癌的研究进展(第5页)》